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Abstract
Background
Human Herpes Virus 8 (HHV8) can cause Kaposi’s Sarcoma (KS) in immunosuppressed
individuals. However, little is known about the association between chemotherapy or
hematopoietic stem cell transplantation (HSCT), circulating HHV8 DNA levels, and clinical
KS in HIV-1-infected individuals with various malignancies. Therefore, we examined the
associations between various malignancies, systemic cancer chemotherapy, T cell pheno-
types, and circulating HHV8 DNA in 29 HIV-1-infected participants with concomitant KS or
other cancer diagnoses.
Methods
We quantified HHV8 plasma viral loads and cell-associated HHV8 DNA and determined the
relationship between circulating HHV8 DNA and lymphocyte counts, and markers of early
and late lymphocyte activation, proliferation and exhaustion.
Results
There were no significant differences in plasma HHV8 DNA levels between baseline and post-
chemotherapy time points or with the presence or absence of clinical KS. However, in two par-
ticipants circulating HHV8 DNA increased following treatment for KS or HSCT for lymphoma,.
We observed an approximately 2-log10 reduction in plasma HHV8 DNA in an individual with
KS and multicentric Castleman disease following rituximab monotherapy. Although individuals
with clinical KS had lower mean CD4+ T cell counts and percentages as expected, there were
no significant associations with these factors and plasma HHV8 levels. We identified increased
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proportions of CD8+ and CD4+ T cells expressing CD69 (P = 0.01 & P = 0.04 respectively),
and increased CD57 expression on CD4+ T cells (P = 0.003) in participants with detectable
HHV8.
Conclusion
These results suggest there is a complex relationship between circulating HHV8 DNA and
tissue-based disease in HIV-1 and HHV8 co-infected individuals with various malignancies.
Introduction
Human Herpes Virus 8 (HHV8) is the causative agent of Kaposi’s Sarcoma (KS), a malignancy
involving epithelial and other cells (e.g. B cells) of the lymphatic and circulatory systems.
HHV8 infection alone is insufficient to cause clinical KS, and KS lesions are usually identified
in individuals with significant immune dysregulation (e.g. HIV infection with low CD4+ T cell
counts or immunosuppression following organ transplantation) [1,2]. KS can be an insidious
disease with major associated morbidity, but may also improve clinically following recovery of
CD4+ T cell counts or with specific chemotherapeutic intervention [3,4,5]. Iatrogenic KS is
largely attributed to corticosteroid treatment, but B cell targeted therapies, such as rituximab,
are also known to trigger HHV8 reactivation and the development of KS [6,7,8]. However, less
is known about the significance of circulating levels of HHV8 without clinical KS in HIV
infected individuals.
While it is well established that the tissue presence of HHV8 in combination with immuno-
suppression leads to the development of clinical KS, there are limited data on the dynamics of
circulating HHV8 in HIV infected individuals receiving cytoreductive chemotherapies for var-
ious malignancies, or the impact of anti-tumor therapies on HHV8 viremia [3]. Furthermore,
it is possible that circulating HHV8 may be associated with increased immune activation and
exhaustion, but studies focusing on the associations between HHV8 viremia, CD4+ T cell
counts, and lymphocyte phenotypes in the setting of HIV and malignancy are lacking. To
address these issues, we examined the associations between different systemic cancer chemo-
therapies for KS and other malignancies with T cell counts and phenotype, circulating HHV8
DNA, HIV infection and clinical KS.
Methods
Plasma and peripheral blood mononuclear cells (PBMCs) were obtained from a longitudinal
cohort of HIV-infected individuals with a malignancy requiring systemic chemotherapy from
2012 until 2015 at Harvard Cancer-Center-affiliated institutions (Beth-Israel Deaconess Medi-
cal Center, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, and Massachusetts
General Hospital). Whenever possible, whole blood samples were collected prior to initiation
of chemotherapy, during chemotherapy and every six months thereafter. Longitudinal sam-
pling was unavailable in some participants due to loss of follow-up, study adherence, or death.
The Office for Human Research Studies of Dana-Farber/Harvard Cancer Center approved the
study and written signed informed consent was obtained from each participant before sample
collection.
Plasma was separated from cells and purified via double centrifugation, PBMC were iso-
lated using density gradient centrifugation and cryopreserved until processing as previously
described [9]. CD4+ T cells were depleted from total PBMC using the EasySep Human CD4+
T Cell Positive Selection kit (StemCell Technologies, Canada) prior to DNA extraction. Plasma
HHV8 in HIV-1 infected individuals receiving cancer chemotherapy and SCT
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and PBMC HHV8 DNA was extracted using Qiamp Blood Mini Kit (Qiagen, USA) following
the manufacturer’s standard protocol.
Quantification of HHV8 DNA was performed on a LightCycler480 real-time PCR machine
(Roche, USA) using a previously described method [10]. Results for plasma HHV8 DNA
determination were adjusted by volume to obtain HHV8 DNA copies/mL; results of HHV8
DNA determination in CD4+ T cell-depleted PBMC HHV8 DNA results were normalized to
cell counts based on quantitative PCR of the conserved human CCR5 gene as described [9,11].
IgG antibodies specific to HHV8 were measured by commercial immunofluorescence assay
(Quest Diagnostics, Chantilly, VA) to provide an indication of prior HHV8 exposure.
Thawed, cryopreserved PBMCs were stained with Fixable Blue Dead Cell Stain, anti-CD3
(Invitrogen, USA), anti-CD4 (eBioscience, USA), anti-CD8, anti-CD38, anti-HLA-DR, anti-
CD57, and anti-CD69 (BD Biosciences, USA). Following surface staining, cells were fixed, per-
meabilized and stained for intracellular anti-Ki-67 (BD). Samples were analyzed on a BDTM
LSRII flow cytometer using FACSDivaTM software (BD) and FlowJo (Tree Star, Inc., USA).
Statistical analyses were performed using Prism 5.0 (GraphPad Software). Non-parametric
Mann Whitney U tests were used to identify significance between groups.
Results
We analyzed samples from 29 HIV-1-infected individuals collected before initiation of cancer
chemotherapy (or at the first collection time point during chemotherapy if no pre-treatment time
point was available), and/or following completion of treatment. Of these individuals, 15 subjects
were diagnosed with non-Hodgkin lymphoma (NHL), one diagnosed with acute myelogenous
leukemia (AML), and one diagnosed with renal cell carcinoma (RCC). Table 1 describes demo-
graphics, treatment history and HHV8 testing results for these participants with non-KS malig-
nancies. Six participants were diagnosed with clinical KS (one had concomitant multicentric
Castleman disease; MCD) as summarized in Table 2. Plasma and HHV8 levels at each collection
time point for all study participants are shown in S1 Table. While 12 of 23 participants with non-
KS malignancies (excluding HSCT recipients) received combination chemotherapy including
rituximab, only one individual with KS/MCD received rituximab treatment alone. With the
exception of six participants (two with active KS, and four with NHL), all patients were on combi-
nation antiretroviral therapy (ART) throughout this study and maintained HIV-1 viral loads of
<1000 RNA copies/mL. One of the KS participants initiated ART post baseline sampling, and
remained on ART throughout subsequent collection time points. 12 of 29 total participants,
including all individuals with clinical KS had detectable anti-HHV8 antibodies. Six of these 12
individuals also had detectable HHV8 DNA. Interestingly, one participant with clinical KS had
no detectable HHV8 DNA, and, of 15 individuals with NHL, four had detectable HHV8 DNA
but no detectable anti-HHV8 antibodies. HHV8 DNA was detected in a higher number of plasma
samples than in CD4+ T cell-depleted PBMC, although a significant positive correlation between
plasma and cellular DNA copies was observed (P = 0.001; Fig 1A). No significant correlations
were observed between plasma or cell-associated HHV8 DNA and plasma HIV-1 RNA.
Overall, there were no significant differences between baseline and post-chemotherapy/
HSCT plasma HHV8 DNA levels in individuals with or without baseline clinical KS. Of note,
participants with clinical KS following cancer therapy had significantly higher levels of plasma
HHV8 DNA than those with other malignancies (P = 0.034; Fig 1B). The higher levels of HHV8
DNA between pre-chemotherapy time points for participants with or without clinical KS were
not statistically significant. Longitudinal sampling allowed paired analyses on six participants as
shown in Fig 1C. Two individuals experienced increased HHV8 DNA following either KS-tar-
geted chemotherapy or allogeneic HSCT for lymphoma. Interestingly, the increase in HHV8
HHV8 in HIV-1 infected individuals receiving cancer chemotherapy and SCT
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DNA in the participant with clinical KS occurred in the setting of clinical improvement of dis-
seminated lesions. In the HSCT recipient, HHV8 DNA was not detected in cells prior to HSCT,
Table 1. Patient Demographics, HHV8 DNA and Antibody Positivity, and clinical Details for participants with non-KS malignancies.
Pt Sex HHV8 Antibody HHV8 DNA ART at Time of Sampling Clinical Diagnosis Cancer Treatment
7 M - + No NHL N/A
8a F - - No NHL R-CODOX-M/IVAC
9 M - + Yes NHL R-EPOCH
10 M - + Yes NHL R-CHOP
11 M - - Yes NHL CHOP, GDP,
12 M - - Yes NHL R-CHOP,
13 M + - No NHL R-CHOP
14 M - - Yes NHL R-CHOP
15a M + + Yes NHL R-EPOCH, DHAP
16 M + - Yes NHL R-CHOP, R-ICE
17 M + - Yes NHL R-EPOCH
18 M - - No NHL EPOCH, R-ICE
19 M - - -b NHL R-EPOCH
20 M - - Yes NHL R-ICE
21 M - - Yes HL ABVD
22 M - - Yes HL ABVD
23 M - - Yes AML Cytarabine-based
24 M - - Yes RCC carboplatin/gemcitabine
25 M - - Yes HL Autologous HSCT
26 M + - Yes HL Allogeneic HSCTc
27 M - - Yes HL Allogeneic HSCTc
28 M + - Yes HL Allogeneic HSCTc
29a Ma - + Yes NHL Allogeneic HSCTc
Pt = participant; NHL = non-Hodgkin lymphoma; HL = Hodgkin’s Lymphoma; RCC = renal cell carcinoma; AML = acute myeloid leukaemia; R-EPOCH = rituximab,
etoposiode, prednisone, vincristine, cyclophosphamide, doxorubicin; R-CODOX-M/IVAC = rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/
ifosfamide, etoposide, cytarabine; GDP = R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; DHAP = dexamethasone, cytarabine,
cisplatin; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; HSCT = hematopoietic stem cell transplantation;
a longitudinal data on detectable HHV8 levels were available
b Unknown
c Conditioning regimen included busulfan and fludarabine
https://doi.org/10.1371/journal.pone.0197298.t001
Table 2. Patient Demographics, HHV8 DNA and Antibody Positivity, and clinical Details for participants with biopsy proven KS.
Pt Sex HHV8 Antibody HHV8 DNA ART at Time of Sampling Clinical Details Chemotherapy
1a M + + Yesb Disseminated KS (skin, lung) Paclitaxel/Doxorubicin
2 M + + Yes Extensive disseminated KS (skin, viscera, lung), Paxlitaxel
3a M + + Yes Disseminated cutaneous KS Doxorubicin
4 M + - Yes Rectal mass and lymph node KS Doxorubicin
5 M + + Yes Disseminated KS (skin, mucosa, pleura, lymph nodes) Doxorubicin
6a M + + Yes Cutaneous KS and concomitant MCD Rituximab
Pt = participant; KS = Kaposi’s Sarcoma; MCD = multicentric Castleman disease
a longitudinal data on detectable HHV8 levels were available
b Patient started ART after baseline, pre-chemotherapy sampling
https://doi.org/10.1371/journal.pone.0197298.t002
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but rose to 9,888 copies/106 CD4+ T cell-depleted PBMC 48 days following transplantation (S1
Table). In contrast, HIV DNA decreased from 12,363 copies/106 CD4+ T cells at baseline to
6,695 copies/106 CD4+ T cells following HSCT.
No significant differences in CD4+ T cell counts or percentages were identified between
individuals with or without detectable plasma HHV8 DNA (Fig 1D). However, individuals
with clinical KS had significantly lower mean CD4+ T cell counts and percentages than indi-
viduals without KS but with evidence of prior HHV8 exposure (i.e. HHV8-specific antibodies
or detectable HHV8 DNA, Fig 1E).
Finally, significantly increased levels of CD69, an early activation marker, were identified
on both CD8+ and CD4+ T cells in participants with detectable HHV8 compared to those
without circulating DNA (P = 0.01 and P = 0.04, respectively; Fig 1F). However, no significant
intergroup differences in the co-expression of CD38/HLA-DR (late activation markers) or
Ki67 (intracellular proliferation marker) were observed (Fig 1G and 1H). CD57, a marker of
immune exhaustion, was found to be significantly increased on CD4+, but not CD8+ T cells in
participants with detectable HHV8 DNA (P = 0.003; Fig 1I).
Discussion
Circulating HHV8 levels have been described as a predictor of clinical KS development [12,13],
and all individuals receiving chemotherapy for KS or lymphoma in a prior study investigating
HIV and malignancy reported decreased levels of circulating HHV8 in PBMC and plasma com-
pared to baseline [3]. In our study, systemic cancer chemotherapy or transplantation had little
consistent effect on circulating HHV8 burden. As a result, the relationship between circulating
HHV8 DNA and clinical disease is likely more complex. For example, one participant in our
study experienced improvement in disseminated KS lesions despite increasing circulating HHV8
DNA levels. Of note, a prior case report of an individual treated with rituximab, doxorubicin and
valganciclovir, also demonstrated discordance between circulating HHV8 and clinical KS [14].
Furthermore, a HSCT recipient in our study with detectable HHV8 experienced a 4-log10 in-
crease in HHV8 DNA copies/106 cells 48 days following transplantation, despite an overall
reduction in CD4+ T cell-associated HIV-1 DNA. It has been reported that allogeneic HSCT dra-
matically reduces HIV-1 DNA burden in the setting of ART following the development of full
donor-cell chimerism [15], but the impact of HSCT on HHV8, including transplant condition-
ing and subsequent immune dysfunction, is underreported. While anecdotal, increasing HHV8
levels in our HSCT recipient may be a result of immune dysfunction following transplantation
and persistent tissue sources of virus that escape donor cell replacement of the recipient hemato-
poietic compartment. Overall, four of five participants with either KS or lymphoma for whom
longitudinal data was available experienced decreasing circulating HHV8 DNA levels. For
Fig 1. Relationships between circulating HHV8 DNA, Kaposi sarcoma (KS), and lymphocyte phenotypes in individuals
with HIV-1 and concomitant malignancy. (A) Plasma and CD4+ T cell-depleted PBMC-associated HHV8 DNA are
significantly and positively correlated by Spearman rank correlation analysis. (B) Individuals with clinical KS have higher plasma
HHV8 DNA levels than those with other malignancies and evidence of prior HHV8 exposure (e.g. positive HHV8-specific
antibodies or detectable HHV8 DNA), but there were no overall significant differences between pre- or post-chemotherapy time
points by unpaired Mann Whitney U analysis. (C) Two individuals experienced>1-log10 increase in HHV8 DNA following
treatment for KS or allogeneic stem cell transplantation for lymphoma. (D) No differences in CD4+ T cell counts or percentages
were identified between participants with and without detectable circulating HHV8 DNA, despite significantly lower CD4+ T
cell counts and percentages in individuals with clinical KS (E). Individuals with circulating HHV8 had significantly increased
expression of CD69 (early activation marker) on both CD4+ and CD8+ T cells (F), but no differences in late markers of
activation (G) or proliferation (H). (I) Significantly higher numbers of CD4+ T cells expressed CD57 (lymphocyte exhaustion
marker) from individuals with circulating HHV8. P values calculated from Mann Whitney U analyses and data points represent
all sample time points from all participants. HSCT = hematopoietic stem cell transplantation.
https://doi.org/10.1371/journal.pone.0197298.g001
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example, the two participants with NHL and decreasing HHV8 DNA levels received doxorubicin
as part of their chemotherapy for diffuse large B cell lymphoma, which has known activity against
KS. Further study of HHV8 responses to various chemotherapeutic agents in larger cohorts of
HIV-infected individuals is warranted. Rituximab, a monoclonal antibody that targets CD20
expressed on B cells, is thought to reactivate HHV8 viremia and lead to the development of clini-
cal KS in both HIV-infected and uninfected individuals [16,17,18]. Interestingly, the participant
with MCD/KS had a 1.9-log10 reduction in plasma HHV8 following rituximab monotherapy,
but also recently started on suppressive antiretroviral therapy which may have led to improved
anti-HHV8 immune responses.
In concordance with prior HIV-1 and lymphoma studies, we found that the prevalence of
circulating HHV8 DNA in individuals with clinically evident KS was higher than in individu-
als with NHL (33%) [3]. In addition, four of ten individuals with detectable HHV8 DNA in
our study did not have detectable anti-HHV8 antibodies as measured by commercial assay;
discordance between HHV8 antibody testing and viral DNA has also been reported in HIV-
1-infected individuals [19]. It is possible that antibody responses may be impaired due to
immune suppression in the setting of concomitant HIV disease and malignancy. Despite
detectable HHV8 in individuals with NHL, no individuals with Hodgkin’s lymphoma (HL)
had detectable HHV8 DNA in plasma (two had detectable anti-HHV8 antibodies). Four of six
of these individuals received stem cell transplant (three allogeneic and one autologous) for
refractory disease and all completed systemic chemotherapy prior to sampling and HSCT. The
lack of detectable HHV8 DNA in participants with HL may be a result of limited sample size
or HSCT conditioning and donor-cell engraftment. As a result, longitudinal studies of HHV8
burden in a larger numbers of individuals with HL are needed.
The associations between plasma HHV8 DNA and markers of T cell activation, prolifera-
tion, and exhaustion in the setting of HIV and concomitant hematological malignancies have
yet to be defined. We observed a greater frequency of CD4+ T cells expressing a marker of
early immune activation from participants with circulating plasma HHV8, but no significant
differences in expression of markers of late lymphocyte activation or T cell proliferation. How-
ever, significantly higher frequencies of CD4+ T cells expressing exhaustion markers were
identified. These results are in the context of an HIV-1-infected population that typically has
higher levels of immune activation and exhaustion that may have masked differences directly
due to HHV8 or clinical KS.
In summary, this study demonstrates that concomitant cancer diagnosis in HIV infected
individuals, chemotherapy and HSCT have variable associations with presence and levels of
circulating HHV8, but that plasma HHV8 is associated with early markers of lymphocyte acti-
vation and exhaustion. Further study is therefore warranted to determine whether or not
HHV8 viremia is a cause or effect of increased T cell activation and exhaustion, and to deter-
mine the long-term effects of circulating HHV8 DNA on clinical outcomes in HIV-infected
individuals.
Supporting information
S1 Table. Plasma and HHV8 levels at each collection time point for all study participants.
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